Future Thought @futurethought - Twitter Profile

over 2 years ago

Are you solving the below problems with the solution set of the 2020s and 2030s? Would love to partner with you. #discover

19

46

9

25

79K

futurethought retweeted

Ashvattha Therapeutics

@AshvatthaTx

over 1 year ago

Time to Change the Treatment Paradigm - No More Needles in the Eye It's 2025, and we have an alternative to the pain faced by millions of wAMD and DME patients - an at-home subcutaneous administration once per month that treats both eyes, dramatically reducing the need for the need for needles in the eye without ocular OR systemic safety issues. Very exciting to be releasing the Phase 2 data on Saturday, Feb 8!

2

10

3

7K

futurethought retweeted

Jay Z

@superjz

over 1 year ago

💪🙌

1

10

4

0

2K

futurethought retweeted

Ashvattha Therapeutics

@AshvatthaTx

over 1 year ago

Ashvattha is the first therapeutics platform to target and reprogram macrophage and microglia (two important immune cells) which are known to be responsible for neurological disorders to cancer, ophthalmic diseases to autoimmune disorders. We're excited to partner with @tribecap and @arjunsethi for our $50M Series B extension. Thankful to @NatCapCentral for their support since our incubation! /1

2

38

8

9

29K

Who to follow

Tommy Gale

@otmmygale

Zeke spyin' low beneath the city lights, silent watcher of the forgotten alleys.

Imaginext™ Figures and Playsets

futurethought retweeted

Jay Z

@superjz

over 1 year ago

Checkpoint inhibitors only work in 15-40% of patients who have cancers. They are miracle drugs but could use some help. @AshvatthaTx has developed a radiopharmaceutical that can solve the problem.

0

25

7

5

27K

futurethought retweeted

Ashvattha Therapeutics

@AshvatthaTx

over 1 year ago

HDTs are made from drug-dendrimer conjugates and in four health volunteer safety studies and 2 Phase 2 studies we find repeated safety in human subjects some of whom have been dosed chronically for forty weeks. This is exciting for us and patients who could benefit from our drug pipeline for Wet AMD/DME, Chronic Fatigue Syndrome/ME, solid tumors (targeting tumor associated macrophage), Multiple Sclerosis.

AshvatthaTx's tweet photo. HDTs are made from drug-dendrimer conjugates and in four health volunteer safety studies and 2 Phase 2 studies we find repeated safety in human subjects some of whom have been dosed chronically for forty weeks. This is exciting for us and patients who could benefit from our drug pipeline for Wet AMD/DME, Chronic Fatigue Syndrome/ME, solid tumors (targeting tumor associated macrophage), Multiple Sclerosis.

0

6

3

2

702

futurethought retweeted

Ashvattha Therapeutics

@AshvatthaTx

over 1 year ago

A hydroxyl dendrimer, the basis for all our drugs and the entire class of HDTs (hydroxyl dendrimer therapeutics), of which we have 32 in our pipeline. Every generation 4 dendrimer has 64 hydroxyl arms that can be loaded with the same or different active molecule making for a potent drug platform.